Clinical Trials Browser

Phase 2 × idelalisib × 90 days × Clear all

NCT02135133 2026-03-17

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Phase 2 Completed

27 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell